IRIDEX Corp: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über IRIDEX Corp Unternehmen

IRIDEX Corporation is an ophthalmic medical technology company. The Company is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.

IRIDEX Corp Informationen



BörsenkürzelIRIX

Name des UnternehmensIRIDEX Corp

IPO-datumFeb 16, 1996

CEOMercer (Patrick)

Anzahl der mitarbeiter93

WertpapierartOrdinary Share

GeschäftsjahresendeFeb 16

Addresse1212 Terra Bella Ave

StadtMOUNTAIN VIEW

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl94043

Telefon16509404700

Websitehttps://www.iridex.com/

BörsenkürzelIRIX

IPO-datumFeb 16, 1996

CEOMercer (Patrick)

Führungskräfte von IRIDEX Corp



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. William M. (Will) Moore, Jr.

Independent Director

402.00K

+52000.00%

Mr. Romeo R. Dizon

Chief Financial Officer

121.79K

+2500.00%

Mr. Patrick Mercer

President, Chief Executive Officer, Chief Operating Officer, Director

100.14K

-23850.00%

Ms. Beverly A. Huss

Independent Director

92.64K

+65167.00%

Mr. Scott A. Shuda, J.D.

Independent Chairman of the Board

--

Mr. Yu Hao (Nick) Chen

Independent Director

--

Mr. Bassem Bouhabib

Vice President - International Sales

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. William M. (Will) Moore, Jr.

Independent Director

402.00K

+52000.00%

Mr. Romeo R. Dizon

Chief Financial Officer

121.79K

+2500.00%

Mr. Patrick Mercer

President, Chief Executive Officer, Chief Operating Officer, Director

100.14K

-23850.00%

Ms. Beverly A. Huss

Independent Director

92.64K

+65167.00%

Mr. Scott A. Shuda, J.D.

Independent Chairman of the Board

--

Mr. Yu Hao (Nick) Chen

Independent Director

--

Umsatzaufteilung

Währung: USDAktualisiert: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Retina

6.70M

53.65%

G6

3.54M

28.33%

Other

2.25M

18.02%

Nach RegionUSD

Name

Umsatz

Anteil

United States

5.59M

44.76%

Europe & Middle East & Africa

4.03M

32.31%

Asia/Pacific Rim

2.07M

16.55%

Rest of the Americas

797.00K

6.38%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Retina

6.70M

53.65%

G6

3.54M

28.33%

Other

2.25M

18.02%

Aktionärsstatistik

Aktualisiert: Sun, Feb 1

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Topcon Corp

9.41%

Stanley Manne Trust

6.24%

Paragon JV Partners, LLC

5.82%

The Vanguard Group, Inc.

3.37%

Roland (Brent Alexander)

2.69%

Andere

72.48%

Aktionäre

Anteil

Topcon Corp

9.41%

Stanley Manne Trust

6.24%

Paragon JV Partners, LLC

5.82%

The Vanguard Group, Inc.

3.37%

Roland (Brent Alexander)

2.69%

Andere

72.48%

Aktionärstypen

Aktionäre

Anteil

Corporation

19.75%

Individual Investor

10.78%

Hedge Fund

9.90%

Investment Advisor

4.98%

Venture Capital

1.66%

Investment Advisor/Hedge Fund

1.34%

Research Firm

0.39%

Andere

51.19%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

47

3.14M

18.28%

+220.56K

2025Q3

46

2.61M

15.39%

-533.70K

2025Q2

62

7.58M

45.15%

+346.62K

2025Q1

57

6.59M

39.89%

-547.85K

2024Q4

56

6.67M

40.12%

-576.91K

2024Q3

56

6.58M

39.55%

-791.78K

2024Q2

63

7.41M

45.29%

-103.92K

2024Q1

64

7.34M

45.55%

+258.49K

2023Q4

68

7.28M

45.21%

-25.53K

2023Q3

68

7.58M

47.03%

+345.93K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Topcon Corp

1.62M

9.41%

+6.00K

+0.37%

Apr 01, 2025

Stanley Manne Trust

1.07M

6.24%

--

Apr 01, 2025

Paragon JV Partners, LLC

1.00M

5.82%

--

Sep 30, 2025

The Vanguard Group, Inc.

578.71K

3.37%

-7.10K

-1.21%

Sep 30, 2025

Roland (Brent Alexander)

461.71K

2.69%

+461.71K

--

Apr 01, 2025

Moore (William M)

402.00K

2.34%

+52.00K

+14.86%

Dec 16, 2025

Renaissance Technologies LLC

389.06K

2.26%

+10.30K

+2.72%

Sep 30, 2025

Roland Family Support Trust

223.69K

1.3%

+223.69K

--

Apr 01, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten